Email Updates

You are here

Webinar & Meeting Reports

  • June 1, 2020 to October 30, 2020

    The HIV2020 Conference has been reimagined as a series of virtual convenings that will take place June through October of this year.

  • May 22, 2020

    On Friday, May 22, the HIV Prevention Trials Network (HPTN) held a community webinar to discuss the preliminary results of HPTN 083, a global randomized, controlled, double-blinded study that compared the safety and efficacy of long-acting injectable cabotegravir (CAB LA) to daily oral tenofovir/emtricitabine (TDF/FTC) (Truvada) for pre-exposure prophylaxis (PrEP). The study showed that CAB LA lowered HIV incidence among cisgender men and transgender women who have sex with men.

  • May 18, 2020

    May 18 is HIV Vaccine Awareness Day (HVAD), a day when partners around the world join to celebrate the people, partnerships and science pushing ever closer to a safe, efficacious and accessible vaccine against HIV. Check out AVAC's dedicated HVAD 2020 page, which includes a toolkit, details on related webinars to support advocacy and action and more.

  • May 13, 2020

    Six months? A year? Longer? Never? How long until there’s a vaccine against COVID-19? How is COVID vaccine research moving so quickly? How do HIV vaccine and COVID-19 vaccine research relate and inform each other? On Wednesday, May 13, we conducted a webinar with Jon Cohen, one of the leading journalists covering both HIV and COVID.

  • May 7, 2020

    On Thursday, May 7, AVAC held a webinar, The Power–and Pitfalls–of Modeling for COVID-19 and HIV, to discuss current COVID-19 models, and the benefits and limitations of mathematical models as they apply to both COVID-19 and HIV prevention.

  • April 9, 2020

    Professor Sinead Delany-Moretlwe of Wits RHI talks with community engagement practitioners from trial site communities across Africa on how HIV clinical trials will be affected by the global response to COVID-19.

  • April 2, 2020

    On Thursday, April 2, AVAC held it second webinar on COVID-19 and its relationship to HIV. Dr. Mark Feinberg, CEO of IAVI, shared experiences and lessons from Ebola and HIV vaccine development that might be applied to COVID-19 vaccine development. Dr. Feinberg was joined by Dr. Helen Rees of Wits RHI to discuss the history and role of the Coalition for Epidemic Preparedness Innovations (CEPI), which supports vaccine development against emerging infectious diseases, including COVID-19.

  • March 23, 2020

    On Monday, March 23 we were joined by Dr. Carl Dieffenbach, Director of the Division of AIDS (DAIDS) at the NIH, Lillian Mworeko of ICW-EA and Yvette Raphael of APHA, to answer questions about what we do and don’t know about COVID-19 and HIV, how to track research developments on the HIV front, what this new pandemic might mean for ongoing HIV research, and how the HIV community can contribute to the fight against COVID-19.

  • March 8, 2020 to March 11, 2020

    The annual Conference on Retroviruses and Opportunistic Infections (CROI) will take place March 8-11 in Boston, Massachusetts. Read on to review the coverage, access webcasts of conference sessions and to check out what caught AVAC’s attention.

  • February 19, 2020

    Leaders of HVTN 702 HIV vaccine efficacy trial in South Africa (also known as Uhambo), announced that vaccinations would be stopped early because the vaccine candidate did not prevent HIV. AVAC and APHA held a global webinar to discuss the latest updates on these conversations and reflect on how they may impact HIV prevention globally.

Pages